Table 10.

Higher generation ADC patents

Category	Example IP rights	Assignee	Target	Claim language
2nd medical use	US20110165155	Genentech	HER2	A method for the treatment of metastatic or unresectable locally advanced HER2 positive cancer in a patient comprising administering a therapeutically effective amount of trastuzumab-MCC-DM1 wherein the patient has been previously treated with at least 2 anti-HER2 agents.
Formulation	WO2014143765	Abbvie	EGFR	A formulation comprising an anti-Epidermal Growth Factor Receptor (EGFR) antibody drug conjugate (ADC), a sugar, histidine, and a surfactant, wherein said formulation has a pH of about 5 - 7, and wherein said anti-EGFR ADC comprises an anti-EGFR antibody, or antigen-binding portion thereof, conjugated to an auristatin.